Beijing Company Profile
What is the competitive landscape for BEIJING
BEIJING has five approved drugs.
There is one tentative approval on BEIJING drugs.
Drugs and US Patents for Beijing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Yiling | ORVATEN | midodrine hydrochloride | TABLET;ORAL | 076725-001 | Nov 3, 2004 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Beijing | NIACIN | niacin | TABLET, EXTENDED RELEASE;ORAL | 214428-001 | Nov 22, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Beijing Yiling | ORVATEN | midodrine hydrochloride | TABLET;ORAL | 076725-003 | Nov 3, 2004 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Beijing Jialin | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 217133-002 | Oct 30, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Beijing Yiling | ORVATEN | midodrine hydrochloride | TABLET;ORAL | 076725-002 | Nov 3, 2004 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Beijing | NIACIN | niacin | TABLET, EXTENDED RELEASE;ORAL | 214428-002 | Nov 22, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Beijing Tide Pharm | COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | TABLET;ORAL | 206036-001 | Oct 14, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

